Company research
ADVANZ PHARMA Corp.
CIK 1642271Updated Nov 16, 2026
Securities
Historical securities (2)
CHEHF · OTC · equity · closed Jun 29, 2015CXRXF · OTC · equity · closed Jun 11, 2021Name history
Concordia International Corp. · through Nov 29, 2018Concordia Healthcare Corp. · through Jun 20, 2016
CHEHF price & chart
Historical security
This listing closed Jun 29, 2015. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
No filing activity has been returned.
Financials
FY 2017 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2017 | FY 2016 |
|---|---|---|
| Cash flows from financing activities: | ||
| Dividends paid | —Source | —Source |
| Additional Financial Items | ||
| AdjustmentsForIncomeTaxExpenseUSD | -36,757,000Source | -34,801,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 8,711,000Source | 30,753,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -72,891,000Source | 128,574,000Source |
| DividendsPaidClassifiedAsFinancingActivitiesUSD | 0Source | 11,477,000Source |
| GeneralAndAdministrativeExpenseUSD | 50,690,000Source | 56,455,000Source |
| GoodwillUSD | 244,957,000Source | 707,930,000Source |
| IncreaseDecreaseInWorkingCapitalUSD | -42,440,000Source | -6,088,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 294,297,000Source | 251,734,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 0Source | 350,000,000Source |
| ProceedsFromIssuingSharesUSD | 0Source | 0Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 57,279,000Source | 18,193,000Source |
income statement · annual statements
| Line item | FY 2017 | FY 2016 |
|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source |
| Total RevenueUSD | 626,169,000Source | 816,159,000Source |
| Additional Financial Items | ||
| ApplicableTaxRatenumber | 0.27Source | 0.27Source |
| BasicEarningsLossPerShareUSD per share | -31.1Source | -25.79Source |
| CurrentTaxExpenseIncomeUSD | 18,491,000Source | 36,846,000Source |
| DeferredTaxExpenseIncomeUSD | -55,248,000Source | -71,647,000Source |
| DepreciationAndAmortisationExpenseUSD | 228,387,000Source | 184,758,000Source |
| DilutedEarningsLossPerShareUSD per share | -31.1Source | -25.79Source |
| EmployeeBenefitsExpenseUSD | 46,462,000Source | 46,302,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 8,711,000Source | 30,753,000Source |
| GeneralAndAdministrativeExpenseUSD | 50,690,000Source | 56,455,000Source |
| GrossProfitUSD | 435,537,000Source | 594,957,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | 685,287,000Source | 1,129,181,000Source |
| ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossUSD | 1,194,765,000Source | 1,132,243,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | -36,757,000Source | -34,801,000Source |
| ProfessionalFeesExpenseUSD | 51,441,000Source | 41,899,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | -1,590,735,000Source | -1,315,694,000Source |
| ProfitLossBeforeTaxUSD | -1,627,492,000Source | -1,348,894,000Source |
| ProfitLossFromOperatingActivitiesUSD | -1,164,948,000Source | -942,307,000Source |
| ResearchAndDevelopmentExpenseUSD | 31,482,000Source | 40,637,000Source |
| RevenueFromInterestUSD | 61,302,000Source | 21,671,000Source |